leukemia
EMA's CHMP Recommends Novartis' Scemblix for TKI-Intolerant Chronic Myeloid Leukemia Patients
The committee recommended the STAMP inhibitor for previously treated Philadelphia chromosome-positive CML patients based on data from the ASCEMBL trial.
Daiichi Sankyo Aims for Vanflyta Approvals in FLT3-ITD AML Outside of Japan
The firm will submit data from a Phase III trial, in which the drug plus chemotherapy reduced the risk of death by 22.4 percent compared to just chemo.
Oryzon Receives €1.9M Grant From European Commission to Develop Targeted AML Drug
The grant funding will in part support a clinical trial of iadademstat in patients with acute myeloid leukemia whose tumors bear a mutation in FLT3.
FDA Approves Servier's Tibsovo, Chemo Combination for Newly Diagnosed IDH1-Mutated AML
The agency approved Tibsovo plus azacitidine for patients over the age of 75 or those with comorbidities preventing them from receiving intensive upfront chemo.
The startup is evaluating its TumorTag technology in a Phase I trial with Seattle Children's Hospital that will serve as the proof of concept for its use with Umoja's in vivo CAR T-cell therapy.